摘要
目的探讨血清TBX3、CA15-3及CEA联合检测在乳腺癌诊断中的临床价值。方法收集140例乳腺癌患者血清标本作为实验组,78例良性乳腺疾病患者血清标本作为良性对照组,100例健康女性血清标本作为正常对照组。血清TBX3含量采用ELISA法检测,血清CA15-3和CEA表达水平用化学发光法检测。所有数据采用SPSS 18.0软件进行统计分析。结果100例健康女性血清TBX3含量为1.72(1.12～2.49)ng/ml,按百分位数法(P95)确定其正常人群上限界值为5.50ng/ml。与良性对照组相比,乳腺癌组血清TBX3、CA15-3和CEA含量均显著升高,差异有统计学意义(P<0.05)。以临床分期为参照指标,TBX3、CA15-3及CEA在Ⅳ期乳腺癌患者血清中的表达水平明显高于其他各期患者(P<0.05)。血清TBX3、CA15-3和CEA对全组乳腺癌的敏感度分别为48.57%、36.43%和31.43%,特异性分别为91.03%、98.72%和100.00%,准确度分别为68.33%、58.72%和55.96%。血清TBX3、CA15-3和CEA联合检测对乳腺癌的敏感度为60.00%,特异性为89.74%,准确度为70.64%。在64例复发或转移性乳腺癌中,血清TBX3、CA15-3和CEA的敏感度分别为64.06%、68.75%、62.50%,而三者联合检测的敏感度则高达79.69%。联合检测与单项指标检测相比,诊断敏感度明显提高(P<0.05)。结论血清TBX3、CA15-3和CEA联合检测能提高乳腺癌的诊断敏感度,对乳腺癌的临床诊断、病期判断以及监测复发或转移方面均有重要价值。
Objective To investigate the clinical value of combined test of serum TBX3, CA15 - 3 and CEA levels in the diagnosis of mastocarcinoma. Methods Three hundred and eighteen females were enrolled in this study： one hundred were healthy females;one hundred and forty were histologically confirmed mastocarcinoma and seventy - eight cases were diagnosed with benign breast lesions. Serum level of TBX3 was measured by enzyme linked immunosorbent assay（ELISA） ,and serum levels of CA15 -3 and CEA were detected in the chemiluminescence method. Statistical analysis was performed using SPSS 18.0. Results The serum TBX3 level of healthy females was 1. 72 （ 1.12 - 2.49） ng/ml, and the cut - off value of serum TBX3 for healthy people was 5.50ng/ml. Elevated serum levels of TBX3, CA15 - 3 and CEA was significantly observed among patients with mastocarcinoma compared to benign females（P 〈 0.05 ）. According to clinical -pathologic stage,the levels of TBX3,CAI5 -3 and CEA in serum were statistically higher in stage IV patients than those in stage I - 11I （P 〈 0.05 ）. The sensitivity of serum TBX3, CA15 - 3 and CEA for diagnosis in breast carcinoma were 48. 57% , 36.43% and 31.43% ,and the specificity were 91.03% ,98.72% and 100.00% ,and the aceuraey rates were 68.33% ,58.72% and 55.96% ,respec- tively. In combined assay of serum TBX3, CA15 -3 and CEA for the total mastocarcinoma,the sensitivity was 60.00% ,the specificity was 89.74% ,the accuracy rate was 70.64%. Furthermore,in the 64 mastocareinoma patients with recurrence diseases or distant metastasis, the sensitivity of TBX3 ,CA15 -3 and CEA were 64.06% ,68.75% and 62.50% ,respectively,while the sensitivity of combined detection was up to 79.69%. Compared with the single assay, combined analysis had much higher diagnostic sensitivity （P 〈 0.05 ）. Conclusion The combined detection of serum TBX3, CA15 - 3 and CEA can increase the diagnostic sensitivity,and the serum marker analysis is shown to be significant for the identification of mastocarcinoma, clinical staging evaluation and monitoring relapse or metastasis.
出处
《医学研究杂志》
2013年第4期118-121,共4页
Journal of Medical Research
基金
杭州市科技发展计划项目(20100633B05)
